PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compared to patients staged with FDG-PET/CT only followed by chemoradiation. The planned sample size is 510; including 200 patients in France. In this trial, patients will be assigned in one of the two following treatments arms: * Arm A (control arm): Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations. * Arm B (experimental arm): Pretherapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy. Considering the changing standard treatment landscape of locally advanced cervical cancer, both arms (control arm and experimental arm) may also be treated according to the INTERLACE and KEYNOTE-A18 studies, if applicable, at the discretion of the attending physician. Each patient will be followed up for 5 years. A cost-utility study will be performed in patients included in France. Other countries could be involved in this specific study. It will assess the incremental cost-utility ratio (cost per QALY gained) of para-aortic lymphadenectomy followed by tailored chemo-radiation in patients with positive PALN compared to patients staged with PET/CT only followed by chemo-radiation. This study also has ancillary objectives: * Biologic: To study T cell exhaustion, immune changes during chemoradiation, HPV ctDNA dynamic evolution, and the par-aortic lymph node as a premetastatic niche. * Radiomics: To study the contribution of radiomics and FDG-PET/CT metabolic parameters to predict para-aortic lymph node involvement and clinical outcome. * Senti-PAROLA: To evaluate the accuracy (Sensitivity, specificity, positive and negative predictive value) of the para-aortic sentinel lymph node (SPA) for PALN staging, and to evaluate the prognostic value of low volume metastasis of SPA.

NCT Number	NCT05581121
Lead Sponsor	Institut Claudius Regaud Collaborators: ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Cancer Intergroup (GCIG), Grupo Español de Investigación en Cáncer de Ovario, Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies, Belgian Gynaecological Oncology Group, Swiss GO Trial Group, Institute of Cancer Research, United Kingdom, The Central and Eastern European Gynecologic Oncology Group, Hellenic Cooperative Oncology Group
Conditions	Cervical Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma
Enrollment	510 participants
Start Date	2023-12-20
Primary Completion	2033-12-20 (estimated)
Study Completion	2033-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-07